{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:20:23Z","timestamp":1756383623024,"version":"3.44.0"},"reference-count":19,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:p>\u25bcPitolisant (Wakix\u2014Bioprojet Pharma) is a new treatment for adults with narcolepsy with or without cataplexy. It was licensed for use in the EU in March last year and has orphan drug status.<jats:sup>1<\/jats:sup> Here, we consider the evidence for pitolisant for the treatment of narcolepsy in adults and how it fits with current management strategies.<\/jats:p>","DOI":"10.1136\/dtb.2017.1.0448","type":"journal-article","created":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T09:45:23Z","timestamp":1484300723000},"page":"6-8","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["\u25bcPitolisant for narcolepsy"],"prefix":"10.1136","volume":"55","member":"239","published-online":{"date-parts":[[2017,1,13]]},"reference":[{"key":"2025082800035232000_55.1.6.1","unstructured":"European Medicines Agency, 2015. Assessment report. Wakix [online]. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002616\/WC500204749.pdf [Accessed 14 December 2016]."},{"key":"2025082800035232000_55.1.6.2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.sleep.2014.10.002","article-title":"Clinical and practical considerations in the pharmacologic management of narcolepsy","volume":"16","author":"Thorpy","year":"2015","journal-title":"Sleep Medicine"},{"key":"2025082800035232000_55.1.6.3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1378\/chest.14-1304","article-title":"Central disorders of hyersomnolence","volume":"148","author":"Kahn","year":"2015","journal-title":"Chest"},{"key":"2025082800035232000_55.1.6.4","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2004.42752"},{"key":"2025082800035232000_55.1.6.5","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.5665\/sleep.4810","article-title":"Comparing treatment effect measurements in narcolepsy the sustained attention to response task, Epworth Sleepiness Scale and Maintenance of Wakefulness Test","volume":"38","author":"Van der","year":"2015","journal-title":"Sleep"},{"key":"2025082800035232000_55.1.6.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70225-4"},{"key":"2025082800035232000_55.1.6.7","unstructured":"Modafinil Provigil 100mg tablets. Summary of product characteristics, UK. Teva Pharma BV, June 2012."},{"key":"2025082800035232000_55.1.6.8","unstructured":"Medicines and Healthcare products Regulatory Agency. Serious skin reactions, hypersensitivity and psychiatric symptoms. Drug Safety Update 2008; 1 (8): 5 [online]. Available: http:\/\/webarchive.nationalarchives.gov.uk\/20140625093154\/http:\/mhra.gov.uk\/safetyinformation\/drugsafetyupdate\/con084779 [Accessed 14 December 2016]."},{"key":"2025082800035232000_55.1.6.9","unstructured":"Dexamfetamine sulphate 5\u2005mg tablets. Summary of product characteristics, UK. Auden Mckenzie (Pharma Division) Ltd, June 2016."},{"key":"2025082800035232000_55.1.6.10","unstructured":"Xyrem 500mg\/ml oral solution. Summary of product characteristics, EU. UCB Pharma Ltd, September 2015."},{"key":"2025082800035232000_55.1.6.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01473.x"},{"key":"2025082800035232000_55.1.6.12","unstructured":"Wakix. Summary of product characteristics, EU. Bioprojet Pharma, May 2016."},{"key":"2025082800035232000_55.1.6.13","doi-asserted-by":"publisher","DOI":"10.1046\/j.0954-7894.2002.01314.x"},{"key":"2025082800035232000_55.1.6.14","unstructured":"European Medicines Agency, 2016. Orphan designation [online]. Available: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/regulation\/general\/general_content_000029.jsp. [Accessed 14 December 2016]."},{"key":"2025082800035232000_55.1.6.15","doi-asserted-by":"publisher","DOI":"10.5582\/irdr.3.1"},{"key":"2025082800035232000_55.1.6.16","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2008.06.0016"},{"key":"2025082800035232000_55.1.6.17","unstructured":"European Medicines Agency, 2016. List of medicines under additional monitoring [online]. Available: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/regulation\/document_listing\/document_listing_000366.jsp [Accessed 14 December 2016]."},{"key":"2025082800035232000_55.1.6.18","unstructured":"European Medicines Agency, 2015. Summary of the risk management plan (RMP) for Wakix (pitolisant) [online]. Available http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Risk-management-plan_summary\/human\/002616\/WC500196690.pdf [Accessed 14 December 2016]."},{"key":"2025082800035232000_55.1.6.19","unstructured":"All Wales Medicines Strategy Group, 2016. Pitolisant (Wakix) [online]. http:\/\/www.awmsg.org\/awmsgonline\/app\/appraisalinfo\/2967 [Accessed 14\u00a0December 2016]."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2017.1.0448","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T07:04:06Z","timestamp":1756364646000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2017.1.0448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1,13]]},"published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1136\/dtb.2017.1.0448"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2017.1.0448","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}